A 19-month-old girl with influenza A (H1N1)-associated acute necrotizing encephalitis made a complete neurological recovery despite a severity score of 6. Multimodal immunomodulatory therapy including IVIG, corticosteroids, anakinra, and plasma exchange led to rapid decline in blood cytokine levels. The case underscores early recognition and targeted treatment in young children.
CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.
The FDA granted Breakthrough Therapy designation to NGN-401, Neurogene's gene therapy for Rett syndrome, based on interim data showing durable functional improvements. The company expects to complete pivotal trial dosing in Q2 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07410312 |
BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07281027 |
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" |
NOT_YET_RECRUITING | PHASE3 |
| NCT07138898 |
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
RECRUITING | PHASE2 |
| NCT06666335 |
A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF |
WITHDRAWN | PHASE4 |
| NCT06062966 |
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART) |
RECRUITING | PHASE1 |
| NCT05013450 |
Dupilumab_Metastatic NSCLC |
COMPLETED | PHASE1/PHASE2 |
| NCT03511118 |
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants |
RECRUITING | |
| NCT00339157 |
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS |
COMPLETED | PHASE2/PHASE3 |
